www.cancerimmunotherapy.net - Prof. W. den Otter list of publications

Cancer immunotherapy .net

Prof. Den Otter

cancerimmunotherapy@yahoo.com

Information for doctors

Information for patients

Information on our research group

I want to support this research

Information for doctors

Information voor patienten

Informatie over onze onderzoeksgroep

Ik wil dit onderzoek steunen

List of Publications

1970
1. Den Otter, W. Leverglycogeen van ratten in verschillende meta-bole toe-standen. Een morfologisch en biochemisch onder-zoek. Proefschrift, Utrecht, 1970

1971
2. Den Otter, W. , Van Boxtel, A. B. Th. G. Relation between the gly-cogen content of the liver and liver weight, and its meaning for enzymology. Experientia 27, 1271 (1971)

1972
3. Den Otter, W. , De Minjer, A. Glycogen in the liver during star-vation: A histo-chemical and biochemical inves-tigation. Anato-mical Record 173, 141 (1972) 
4. Den Otter, W. , R. Evans, Alexander, P. Cytotoxicity of murine peritoneal macrophages in tumor allograft immunity. Trans-plan-tation 14, 220, 1972. 
5. Den Otter, W. , Tuit, G. Causes of the zonal distribution of gly-cogen in the liver acinus after a fat-rich diet. Glyco-gen depo-sition in the acini of rat livers during "normal" and "rever-sed" perfusion. Anatomical Record 173, 325 (1972)

1973
6. Den Otter, W. , Blikkendaal-Lieftinck, L. F. , Koten, J. W. Causes of zonal distribu-tion of glycogen in the liver acinus after a fat-rich diet. Experientia 29, 545 (1973) 
7. Den Otter, W. , Bras, G. Bespreking van: H. S. Postuma: Para-bio-sis and tumor growth, Proefschrift, 1973. Nederlands Tijd-schr. Geneeskunde, 117, 1655, 1973. 
8. Den Otter, W. , Runhaar, E. , Ruitenbeek, E. A. Concomitant immu-nity in a muri-ne syn-ge-neic lymphoma system. J. Intern. -Res. Comm. 1, no. 3, p. 24, 1973. 
9. Dullens, H. F. J. , Den Otter, W. Eradication of lymphoma cells with alloge-neic immune peritoneal cells. Experientia 29, 479, 1973. 
10. Pels, E. , Den Otter, W. A cytophylic factor from chal-lenged immune peri-toneal lympho-cytes renders macrophages specifi-cal-ly cytotoxic. Intern. Res. Comm. System (73-4) 17. 0. 4, April 1973. 
11. Pels, E. , Den Otter, W. A cytophylic factor from challenged immune peri-toneal lympho-cytes renders macrophages specifi-cal-ly cytotoxic. J. Inter-nat. Res. Comm. 1, no. 2, p. 28, 1973.

1974
12. Den Otter, W. Concentrations in vitro of various enzymes in liver homo-genates during the first few days of a period of star-vation. Archives In-ternationales de Phy-siologie et de Bioche-mie 82, 611, 1974. 
13. Den Otter, W. , Evans, R. , Alexander, P. Differentiation of im-munologi-cally spe-cific cytotoxic macro-phages into two types on the basis of radio-sensitivity. Trans-plantation 18, 421, 19-74. 
14. Den Otter, W. , Runhaar, E. A. , Ruitenbeek, E. A. , Dullens, H. F-. J. Site-dependent diffe-rences in rejection of tumor cells with and without pre-immunization. Europ. J. Immunol. 4, 444, 1974.
15. Dullens, H. F. J. , Den Otter, W. Therapy with allogeneic immune peritoneal cells. Cancer Res. 34, 1726, 1974. 
16. Dullens, H. F. J. , Kingma, F. J. , Den Otter, W. Immune thera-py with allo-geneic hyperim-mune peritoneal cells in a murine lymp-homa system. Eur. J. Cancer 10, 41, 1974. 
17. Dullens, H. F. J. , Woutersen, R. A. , De Weger, R. A. , Den Otter, W. Eradi-cation of tumour cells by successive injec-tions of allo-gen-eic immune and hyperimmune perito-neal cells in a murine lym-phoma system. Eur. J. Cancer 10, 701, 1974. 
18. Pels, E. , Den Otter, W. A cytophylic factor from challenged immune peri-toneal lymphocytes renders macrophages specifi-cal-ly cytotoxic. Cancer Res. 34, 3089, 1974. 
19. Van Loveren, H. , Den Otter, W. Macrophages in solid tumors. I. Immuno-logically speci-fic effector cells. J. Nat. Cancer Inst. 53, 1057, 1974. -53
20. Van Loveren, H. , Den Otter, W. In vitro activation of armed ma-crophages and the the-rapeutical application in mice. J. Nat. Cancer Inst. 52, 1917, 1974. -3

1975
21. Dullens, H. F. J. , De Weger, R. A. , Woutersen, R. A. , Den Ot-ter, W. Thera-peutic value of antibody-coated immune and hyperimmune macro-phages in a murine lymp-homa system. J. -Nat. Cancer Inst. 54, 77, 1975.

1976
22. Den Otter, W. Bestaat er een weg naar immuuntherapie van kan-ker? Lek-torale rede, 22 november 1976. 
23. Pels, E. , Den Otter, W. Demonstration of specific macro-phage arming factor and spon-taneous macrophage cytotoxici-ty. IRCS 4, 385, 1976.

1977
24. Blikkendaal-Lieftinck, L. F. , Kooij, M. , Kramer, M. F. , Den Ot-ter, W. Cell kine-tics in the liver of rats under normal and ab-normal dietary con-ditions. Exptl. and Mol. Pathol. 26, 184, 1977. 
25. Den Otter, W. Boekbespreking van: H. L. Booij en W. Th. Daems (re-dacteu-ren), 50 jaar na Gorter en Grendel. Nederlands Tijd-schrift voor Geneeskunde 121, 1101, 1977. 
26. Den Otter, W. , Dullens, H. F. J. , Van Loveren, H. , Pels, E. Anti-tumor effect of ma-crophages injected into animals: A review. In: Proc. of the Eures Symp. on the macrophage and cancer (Eds. James, McBride, Stu-art) p. 119, Edinburgh, 1977. -19
27. Van Loveren, H. , Snoek, M. , Den Otter, W. Effects of silica on macrop-hages and lymphocytes. J. Reticuloendothel. Soc. 22, 523, 1977.

1978
28. Den Otter, W. , Pels, E. , Sanders-Van Remmerswaal, E. , Van Vli-et, J. C. J. , Mul-link, J. W. M. A. De keuze van het proefdier voor onderzoek aan cyto-toxische ma-crofagen. Me-dedelingen C. P. B. no. 57, Maart, 1978.

1979
29. Dullens, H. F. J. , Bouman, H. , Den Otter, W. Influence of whole body irra-diation on intra-peritoneal immunity in a syngeneic mouse lymphoma sy-stem. Strahlenthe-rapie 155, 431, 1979. 
30. Dullens, H. F. J. , De Weger, R. A. , Vennegoor, C. , Den Otter, W. Anti-tumor ef-fect of Chlorambucil-antibody complexes in a mu-rine melanoma system. Eur. J. Cancer 15, 69, 1979. 
31. Dullens, H. F. J. , Vennegoor, C. , De Weger, R. A. , Woutersen, F. , Wouter-sen, R. A. , Den Otter, W. Comparison of various forms of therapy in two different mou-se tumor systems. Cancer Tre-atm. Rep. 63, 99, 1979. 
32. Pels, E. , Den Otter, W. Natural cytotoxic macrophages in the peritoneal cavity of mice. Br. J. Cancer, 40, 856, 1979.

1980
33. Kersten, M. C. M. , Pels, E. , De Weger, R. A. , Den Otter, W. Demon-stration of migration inhibitory factor (MIF) in a murine sy-stem using myelomo-nocytic leu-kemia cells. J. of Immunol. Meth. 33, 387, 1980.
34. Pels, E. , De Groot, J. W. , Mullink, R. , Van Unnik, J. A. M. , Den Otter, W. Identi-fication of two different types of mouse peri-to-neal exudate cells with ring-sha-ped nuclei. J. of the Reticu-loendothel. Soc. 27, 367, 1980.

1981
35. Den Otter, W. The effect of activated macrophages on tumor growth in vitro and in vivo. Lymphokines 3, Ed. E. Pick,Ac. Pre-ss, New York, p. 389, 1981. 
36. Den Otter, W. , Dullens, H. F. J. Transfer of macrophages and an-ti-tumour resis-tance. In: Manual of Macrophage Methodo-logy; collection, characteri-zation and function. Ed. H. Marcel Dek-ker Inc. New York, p. 501, 1981. 
37. Dingemans, K. P. , Pels, E. , Den Otter, W. Destruction of murine lympho-ma cells by allo-geneic immune peritoneal macrophages in vitro. An ul-trastructural study. J. Nat. Can-cer Inst. 66, 67, 1981.
38. Dullens, H. F. J. , Den Otter, W. Murine macrophage cytotoxi-city indu---ced by mas-tocytoma cells, cell-free exudates and extracts. Immunopharmaco-logy 3, 241, 1981. 
39. Dullens, H. F. J. , Den Otter, W. A small molecular weight peptide from P815 mas-tocyto-ma cells induces macrophage cytotoxicity. Immunophar-macology 3, 309, 1981. 
40. Dullens, H. F. J. , Van Basten, C. D. H. , De Weger, R. A. , Den Otter, W. Iso-lation of mast cells from murine peritoneal cell popula-tions by velocity sedimentation at unit gravity. J. Immu-nol. Methods 40, 367, 1981. 
41. Van Loveren, H. , De Groot, J. W. , Den Otter, W. Macrophage tumor cells can help to cure murine lymphoma. Proc. Soc. -Exp. -Biol. Med. 167, 207, 1981. 
42. Van Loveren, H. , Van der Zeijst, B. A. M. , De Weger, R. A. , Van Basten, C. , Pij-pers, H. , Hilgers, J. , Den Otter, W. Identifica-tion of the neonatal liver cell line NCTC 1469 as a macrophage-like cell line. J. Reticuloen-dothel. Soc. 29, 443, 1981.

1982
43. De Heer, E. , De Groot, J. W. , Den Otter, W. , Dullens, H. F. J. Pe-ritoneal cell popu-lations during tumor rejection. Int. -J. Tiss. -Reac. 4, 81, 1982. 
44. Den Otter, W. , De Groot, J. W. , Van Basten, C. D. H. , Radema-kers, L. H. P. M. , De Weger, R. A. , Pels, E. Brewer thioglyco-late medium induces different exudates in guinea pigs and mice. Exp. and Molec. Pathol. 36, 403, 1982. 
45. De Weger, R. A. , Dullens, H. F. J. , Den Otter, W. Eradication of murine lymphoma and melanoma cells by chloram-bucil antibody complexes. Im-munol. Rev. 62, 29, 1982. 
46. De Weger, R. A. , Pels, E. , Den Otter, W. The induction of lympho-cytes with the capacity to render macro-pages cyto-toxic in an allogeneic system. Immunology 47, 541, 1982. 
47. Dullens, H. F. J. Hilgers, J. , Van Basten, C. D. H. , De Weger, R. A. De Heer, E. , Den Otter, W. Cell surface antigen pheno-types and enzyme expression patterns of two murine T cell lymphomas deri-ved from early and/or ma-ture thymus cells. Leu-ke-mia Res. 6, 425, 1982. 
48. Dullens, H. F. J. , Hilgers, J. , Spit, B. J. , De Heer, E. , De We-ger, R. A. , Van Bas-ten, C. D. H. , Den Otter, W. Staging, growth properties and metastatic behaviour of a trans-plan-table murine T cell lymphoma. Int. J. Tiss. Reac. 4, 15, 1982. 
49. Van Loveren, H. , Snoek, M. , Den Otter, W. Host macrophages are invol-ved in systemic adoptive immunity against tumors. Expe-rientia, 38, 488, 1982.

1983
50. De Weger, R. A. , Van Loveren, H. , Van Basten, C. D. H. , Oskam, R. , Van der Zeijst, B. A. M. , Den Otter, W. Functional ac-tivities of NCTC 1469 macrophage-like cell line. J. Reticu-loendothel. Soc. 33, 44, 1983. 
51. De Weger, R. A. , Verbakel, J. A. M. , Oskam. R. , Van Den Berg, H. T-. C. M. , Van Basten, C. D. H. , Dullens, H. F. J. , Den Otter, W. An im-proved method of Ig-sedi-mentation sepa-ration for murine peritoneal ma-crophage subpo-pulations. J. Immunol. Meth. 61, 117, 1983. 
52. Den Otter, W. , De Groot, J. W. , Dullens, H. F. J. Eradication of tumor cells after injecti-on into immunized hosts com-pared with the eradication of tumor cells after transfer of immune peri-toneal exudates into tumor-bearing recipients. Cancer Im-mu-nol. Immunot-her. 16, 72, 1983. 
53. Den Otter, W. , Dullens, H. F. J. , De Weger, R. A. Macrophages and antitu-mor reac-tions. Review. Cancer Immunol. -Immunother. 16, 67, 1983. -
54. Dingemans, K. P. , Pels. , E. , Van Dongen, G. , Den Otter, W. De-struction of muri-ne lymphoma cells by allogeneic perito-neal macrophages in vitro: influence of antise-rum. J. Nat. -Cancer Inst. 70, 181, 1983. 
55. Van Loveren, H. , Den Otter, W. Macrophage-like cells as re-search tools in trans-fer expe-riments. Immunobiol. 164, 23, 1983. -2
56. Van Loveren, H. , Hilgers, J. , De Bakker, S. M. , De Weger, R. A. , Brede-roo, P. , Den Otter, W. Macrophage-like cells. Endogeneous peroxidatic activity, cell sur-face anti-gens, and colony stimu-lating factor production. J. Reticuloen-do-thel. Soc. 33, 221, 1983. 
57. Dullens, H. F. J. , Den Otter, W. The use of P815: A warning. Immu-nology Letters 6, 309, 1983.

1984
58. Dullens, H. F. J. , De Weger, R. A. , Den Otter, W. Sponsorship of scientific work. Immu-nology Today 5, 55, 1984. 
59. Dullens, H. F. J. , De Weger, R. A. , Van Loveren, H. , Dinge-mans, K. P. , Pels, E. , Den Otter, W. Macrophages: Important opponents of tumor cells. Internal Med. for Specia-lists 5, 193, 1984. 
60. Haisma, H. , Goedemans, W. , De Jong, M. , Hilkens, J. , Hil-gers, J. , Dul-lens, H. F. J. , Den Otter, W. Specific locali-zation of In-111-labeled mono-clonal antibody versus 67-Ga-labeled immuno-globulin in mice bearing human breast car-cinoma xenografts. Cancer Immunol. Immunother. 17, 62, 1984. 
61. Van Loveren, H. , De Groot, J. W. , Koten, J. W. , Piersma, A. H. , De Weger, R. A. , Den Otter, W. A macrophage factor enhancing the systemic anti-tumour effect of T lympho-cytes. Immunobiol. 166, 118, 1984. -10
62. Pels, E. , De Weger, R. A. , Den Otter, W. Lymphocyte-induced ma-cropha-ge cyto-toxicity. Int. Archs. Allergy appl. Immun. 74, 140 1984. 
63. Pels, E. , De Weger, R. A. , Den Otter, W. Lymphocyte induced ma-crophage cyto-toxicity: Characterization of the macrophage cytotoxicity-inducing lymphocyte. Immunobiol. 166, 84, 1984.

1985
64. De Boer, R. J. , Hogeweg, P. , Dullens, H. F. J. , De Weger, R. A. , Den Otter, W. Ma-cropha-ge T lymphocyte interactions in the anti-tumor immune response: A ma-thematical mo-del. J. Immunology 134, 2748, 1985. 
65. Den Otter, W. Tumor cells do not arise frequently. Cancer Immu-nol. Im-munother. 19, 159, 1985. 
66. Den Otter, W. , Ruitenberg, E. J. Immuunafweer tegen kanker: meer fun-damenteel on-derzoek is nodig om mechanismen op te spo-ren. Kanker, 4/9, 24, 1985. 
67. Dogterom, A. A. , Huber-Bruning, O. , Vernooy, J. E. , Wilbrink, B. , Den Otter, W. , Huber, J. Matrix depletion of young and old human articular cartilage by cultu-red autolo-gous syno-vium fra-gments: a chondrocyte-in-depen-dent effect. Rheuma-tol. Int. 5, 169, 1985. 
68. Dullens, H. F. J. , Hendriks, H. F. J. , Den Otter, W. A low molecu-lar tumor peptide indu-cing macrophage cytotoxicity in vitro. In: Peptide Hormones as Mediators in Immunolo-gy and Oncology. Ed. R. D. Hesch, Raven Press, New York, 1985. 
69. Haisma, H. , Hilgers, J. , Den Otter, W. , Zurawski, Jr. V. R. Iodi-nation of monoclonal anti-bodies for diagnosis and ra-dio-therapy using a convenient one vial method. Br. J. Can-cer 52, 645, 19-85. 
70. Van Loveren, H. , Den Otter, W. , Meade, R. , Terheggen, P. M. A. -B. , As-kenase, P. W. A role for mast cells and the vasoactive amine serotonin in T cell-dependent immunity to tumors. J. Immunol. 134, 1292, 1985.

1986
71. De Weger R. A. , Den Otter W. . Induction of Specific Macrophage Cyto-toxicity. Methods Enzymol. 132, 531, 1986. 
72. De Weger, R. A. , Dullens, H. F. J. , De Boer, R. J. , Den Otter, W. Mathema-tical analysis of the cellular immune reaction against tumour cells. Immu-nology Today 6, 316, 1985. 
73. De Weger R. A. , Runhaar B. A. , Den Otter W. Cytotoxicity by ma-crophages and monocy-tes. Methods Enzymol. 312, 458, 1986. -
74. De Weger, R. A. , Van Loveren, H. , De Groot, J. W. , Rangara-jan, R. , Den Otter, W. Lymphocyte-induced macrophage cyto-toxicity. III. Induction of specific ma-crophage cytotoxi-city is inde-pendent of lipopoly-saccharide. Immunobiol. 171, 170, 1986. 
75. Den Otter, W. Immune surveillance and natural resistance: an evaluation. Cancer Immunol. Immunother 21, 85, 1986. 
76. Den Otter, W. , Koten, J. W. , Der Kinderen, D. J. A New Model for Car-cinogene-sis. Anti-cancer Res. 6, 509, 1986. 
77. Der Kinderen, D. J. , Koten, J. W. , Beemer, F. A. , Tan, K. E. W. -P. , Den Ot-ter, W. Second non-ocular tumors in retinoblas-toma sur-vivors. Ophthalmo-logy 93, 1124, 1986. 
78. DerKinderen, D. J. , Koten, J. W. , Den Otter, W. , Tan, K. E. W. P. , Beemer, F. A. Retino-blastoma, melanoma and pancreatic cancer. Lancet 6 dec. 1986, p. 1335 (Letter to Edi-tor). 
79. Dullens, H. F. J. , Schakenraad, S. , Oostdijk, A. , Vuist, W. , Van der Maas, M. , Den Ot-ter, W. Specific tumoricidal ac-tivity of cytotoxic macrophages and cyto-toxic lymphocy-tes. Cancer Immunol. Immunother. 22, 100, 1986. 
80. Dullens, H. F. J. , Vuist, W. , Van Der Maas, M. , Den Otter, W. The role of host lympho-cytes and host macrophages in an-titumor re-actions after in-jection of sen-siti-zed lympho-cytes and tumor target cells into naive mice. Cancer Immunol. Im-munother. 23, 113, 1986. 
81. Haisma, H. , Ligtenberg, M. , Dullens, H. F. J. , Den Otter, W. Hig-her ADCC of murine peritoneal cells after immunization with allogeneic tumor cells as compa-red with stimu-lation by Adria-my-cin, BCG, and Thioglycolate. Cellular Immuno-logy 101, 454, 1986. 
82. Haisma, H. , Goedemans, W. , De Jong, M. , Hilkens, J. , Hil-gers, J. , Dul-lens, H. F. J. , Den Otter, W. Specific Loca-liza-tion of 111In-Labeled mono-clonal antibo-dy versus 67Ga-la-beled immuno-globulin in mice bearing human breast car-cinoma xeno-grafts. Yearbook of Cancer, chapter 17, 1986. 
83. Huber-Bruning, O. , Wilbrink, B. , Vernooij, J. E. , Bijlsma, J. W-. J. , Den Otter, W. , Hu-ber, J. Contrasting reactivity of young and old human carti-lage to mononu-clear cell factors. J. Rheumatol. 13, 1191 (1986). 
84. Huber-Bruning, O. , Wilbrink, B. , Vernooy, J. E. Bijlsma,J. W. -J. , Den Ot-ter, W. , Huber, J. Contrasting in vitro ef-fects of retinol and mononuclear cell factor on young and old human cartilage. J. Pathol. 150, 21, 1986. 
85. Huber-Bruning, O. , Wilbrink, B. , Vernooij, J. E. , Bijlsma,J. W-. J. , Den Otter, W. , Hu-ber, J. Contrasting reactivity of young and old human carti-lage to mononu-clear cell factors J. Rheumatol. 13, 1191 (1986). 
86. Terheggen, P. , Van Loveren, H. , Den Otter, W. Macrophage-like tumor cells as tools to study chemoattractive activi-ty. J. Leu-kocyte Biology 38, 747, 1985.

1987
87. De Weger, R. A. , Wilbrink, B. , Moberts, R. M. P. , Mans, D. , Oskam, R. , Den Otter, W. Immune reactivity in SL2 lymphoma-bearing mice compa-red with SL2-immu-nized mice. Cancer Immunology Immu-notherapy 24, 25, 1987. 
88. Den Otter, W. Fresh skins for new wine: a new paradigm for tu-mour immuno-logy. In: Tumour Immunology, Mechanisms, Diagnosis, Therapy. W. Den Otter, E. J. Ruitenberg (Eds). Elsevier Scient-. Publ. , Amsterdam (1987), p3. 
89. Den Otter, W. Evaluation of knowledge of in vivo tumorici-dal effector mecha-nisms. In: Tumour Immunology, Mechanisms, Dia-gnosis, Therapy. W. Den Otter, E. J. Ruitenberg (Eds). Elsevier Scient. Publ. , Amster-dam (1987), p. 109. 
90. Den Otter, W. , Koten, J. W. , Der Kinderen, D. J. Carcinogene-sis Revisited. Cancer Inves-tigation 5, 69, 1987. 
91. Den Otter, W. , Ruitenberg, E. J. , (Eds). Tumor Immunology: Me-chanisms, Diagnosis and Therapy. 352 pages. , Elsevier Scient. Publ. , Amsterdam (1987). 
92. Der Kinderen, D. J. , Koten, J. W. , Wolterbeek, R. , Beemer, F. A. , Tan, K. E. W. P. , Den Otter, W. Non-ocular cancer in hereditary retinoblastoma survivors and relatives. Ophthal-mic Paediat-rics and Genetics 8, 23, 1987. 
93. Dullens, H. F. J. , Schakenraad, S. , Den Otter, W. Spontaneous tumor rejec-tion is not al-ways due to a complete cellular rejec-tion. Experimental Pa-thology 31, 33, 1987. 
94. Dullens, H. F. J. , Van der Tol, M. , Lindenmayer, A. , De Weger, R. A. , Den Otter, W. Mathematische modellen en tumor-immunologie. Lab/ABC 8, 16, 1987. 
95. Huber-Bruning, O. , Wilbrink, B. , Vernooij, J. E. , Bijlsma,J-. W. -J. , Den Otter, W. , Huber, J. Differential responses of old human car-tilage explants to synovial- and mononuclear factors. Rheumatolo-gy Inter-national 7, 223, 1987. 
96. Koten, J. W. , Der Kinderen, D. J. , Den Otter, W. Pathogenesis of Burkitt's lymphoma in children. Anticancer Research 7, 869, 1987. 
97. Los, G. , De Weger, R. A. , Moberts, R. M. P. , Van Loveren, H. , Sakkers, R. J. , Den Otter, W. The absence of delayed-type hypersensitivity reactivity in a syngeneic murine tumour system. Immu-nology 62, 89, 1987.

1988
98. Den Otter, W. Who should pay? Nature 334, 98 (1988) (Letter)
99. Den Otter, W. Principles of tumor immunology. Advances in Hygiene and Experimental Medicine. 42, 117 (1988)
100. Den Otter, W. , Koten, J. W. , Der Kinderen, D. J. , Tan, K. E. W-P. Number of events in tumorigenesis. Lancet 20 febr. , 412, 1988. (Letter to Editor) 
101. Der Kinderen, D. J. , Koten, J. W. , Beemer, F. A. , Tan, K. E. W. -P. , Den Ot-ter, W. Preventie van erfelijk retinoblastoom. Kanker 12, 106, 1988. 
102. Der Kinderen, D. J. , Koten, J. W. , Nagelkerke, N. J. N. , Tan, K-. E. -W. P. , Beemer, F. A. , Den Otter, W. Non-ocular cancer in patients with heredita-ry retinoblastoma and their rela-tives. Int. J. Cancer. 41, 499, 1988. 
103. Dullens, H. F. J. , Van Walraven, R. , Klomberg, M. , Radema-kers, L. H. P. M. , De Goey, I. C. E. , Den Otter, W. Lack of correlation between in vivo peroxidatic activity patterns and tumoricidal activity in vitro of peritoneal macrophages after ip. immunization with tumor cells. Immuno-biology. 177, 293, 1988. 
104. Koten, J. W. , Der Kinderen, D. J. , Den Otter, W. Bone sar-comas linked to radio-therapy and chemotherapy in children. New En-gland J. Med. 318, 581, 1988. (Letter to Editor) 
105. Los, G. , De Weger, R. A. , Van de Berg, D. T. W. M. , Sakkers, R. , Den Otter, W. Macrophage infiltration in tumors and tumor surroun-ding tissue: In-fluence of serotonin and sensitized lymphocytes. Cancer Immunol. Immunother. 26, 145, 1988.

1989
106. De Groot, J. W. , De Weger, R. A. , Vandebriel, R. J. , Den Otter, W. Differences in the induction of macrophage cytotoxicity by the specific T-lymphocyte factor SMAF and the lymphokine, Macrophage Activating Factor MAF. Immunobiology 179, 131 (1989). 
107. De Weger, R. A. , Vandebriel, R. J. , Slager, H. , Mans, D. , Van Loveren, H. , Wil-brink, B. , Dullens, H. F. J. , Den Otter, W. Initial immunochemical characterization of Specific Macrophage Arming Factor. Cancer Immunology Immunotherapy. 30, 21 (1989). 
108. Der Kinderen, D. J. , Koten, J. W. , Van Romunde, L. K. J. , Nagel-ker-ke, N. J. D. , Tan, K. E. W. P. , Beemer, F. A. , Den Otter, W. Early diagnosis of bilateral retinoblastoma redu-ces death and blindness. Int. J. Cancer. 44, 35 (1989). 
109. Dullens, H. F. J. , De Weger, R. A. , Van Der Maas, M, Den Besten, P. J. , Den Otter, W. Specific macrophage arming factor (SMAF) activity precedes CTL-activity during tumor rejection. Cancer Immunology Immunotherapy. 30, 28 (1989). 
110. Maas, R. A. , Dullens, H. F. J. , De Jong, W. H. , Den Otter, W. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2. Cancer Research 49, 7037 (1989). 
111. Rutten, V. P. M. G. , Klein, W. R. , De Jong, W. A. C. , Misdorp, W. , Den Ot-ter, W. , Steeren-berg, P. A. , De Jong, W. H. , Rui-tenberg, E. J. Local IL2 therapy in bovine ocular squa-mous cell carcino-ma. A pilot study. Cancer Immunology Immunotherapy. 30, 165 (1989). 
112. Sluijter, F. J. H. , Koten, J. W. , Den Otter, W. Heritability of breast cancer and its role in pre-menopausal cases. Breast Cancer Research and Treatment 14, 39 (1989). 
113. Sluijter, F. J. H. , Koten, J. W. , Den Otter, W. Hereditary cancer and possible risk of mammography. Breast Cancer Research and Treatment 13, 277 (1989). 
114. Strzadala, L. , Rak. I. , Ziolo, E. , Paprocka, M. , Radzikowski, C. , Den Otter, W. Non-cytotoxic asialo-GM1 positive cells exert anti-metastatic activity. Cancer Immunology Immunothe-rapy. 30, 51 (1989). 
115. Vandebriel, R. J. , De Weger, R. A. , Los, G. , Van Loveren, H. , Wiegers, G. J. , Oude Weernink, P. , Den Otter, W. Two specific T-cell factors that initiate immune responses in murine allograft systems. A comparison of biological functions. J. Immunology 143, 66 (1989).

1990
116. Characiejus D, Dullens HFJ, Den Otter W. Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system. Cancer Immunol. Immu-nother. 32, 179 (1990)-2
117. Den Otter W (Editor). Cancer and Heredity. (Een compleet nummer van het tijdschrift Anticancer Research over Cancer and Heredity) Anticancer Res. 10, number 2B, 1990
118. Den Otter W, Koten JW, Van der Vegt BJH, Beemer FA, Boxma OJ, Der-Kinde-ren DJ, De Graaf PW, Huber J, Lips CJM, Roholl PJM, Slu-ijter FJH, Tan KEWP, Van der Heij-den CA, Van der Ven L, Van Unnik JAM. Oncogenesis by mutations in anti-onco-genes: a view. Anticancer Res. 10, 475 (1990) -21
119. Den Otter W, Koten JW, Van der Vegt BJH, Beemer FA, Boxma OJ, De Graaf PW, DerKinderen DJ, Hill FWG, Huber J, Klein WR, Lips CJM, McKenzie RL, Roholl PJM, Sluijter FJH, Tan KEWP, Van der Heij-den CA, Van der Ven L, Van Unnik JAM. Here-ditary cancer and its clinical implications: A view. Anti-cancer Res. 10, 489 (1990) -8
120. DerKinderen DJ, Boxma OJ, Koten JW, Den Otter W. Stochastic theory of oncogenesis. Anticancer Res. 10, 497 (1990).
121. DerKinderen DJ, Koten JW, Tan KEWP, Beemer FA, Van Romunde LKJ, Den Otter W. Parental age in sporadic hereditary retinoblastoma. Am. J. Ophthalmol. 110, 605 (1990). 
122. Gloudemans T, Prinsen I, Van Unnik JAM, Lips CJM, Den Otter W, Sussenbach JS. Insulin-like growth factor gene expression in human smooth muscle tumors. Cancer Res. 50, 6689 (1990) 
123. Nietfeld JJ, Wilbrink B, Den Otter W, Huber J, Huber-Bruning O. The effect of human interleukin-1 on proteoglycan metabolism in human and porcine cartilage explants. J. Rheumatol. 17, 818 (1990) 
124 Koten JW, Den Otter W. Leukemia and lymphoma among young people near Sellafield. Br. Med. J. 300,878 (1999). 
125. Nietfeld JJ, Wilbrink B, Helle M, Van Roy JLAM, Den Otter W, Swaak AJG, Huber-Bruning O. IL-1 induced IL-6 is required for the inhibition of proteoglycan synthesis by IL-1 in human articular cartilage. Arthritis and Rheumatism 33, 1695 (1990) -81
126. Roholl PJM, Skottner A. , Prinsen I, Lips CJM, Den Otter W, van Unnik JAM. Expression of IGF-1 in sarcomas. Histopathol. 16, 455 (1990) 
127. Steerenberg PA, De Jong WH, Geerse E, Aleva BJ, Besselink CMLT, Van Rens BTTM, Rutten VPMG, Poels LG, Scheper RJ, Den Otter W, Ruitenberg EJ. Major histocompatibility-complex class II antigen expression during potentiation of line-10 tumor immunity after intralesional administration of bacillus Calmette-Gu�rin. Cancer Immunol. Immunother. 32, 95 (1990) 
128. Steerenberg PA, De Jong WH, Geerse E, Beuvink A, Scheper RJ, Den Otter W, Ruiten-berg EJ. Major-histocompatibility-Complex class II positive cells and interleukin-2 dependent proliferation of immune T-cells are required to reject carcinoma cells in the guinea pig. Cancer Immunology Immunotherapy 31, 297 (1990) 
129. Steerenberg PA, De Jong WH, Elgersma A, Burger R, Poels LG, Claessen AME, Den Otter W, Ruitenberg EJ. Tumor infiltrating leukocytes (TILS) during progressive tumor growth and BCG-me-diated tumor re-gression. Virchows Archiv. B Cell Pathol. 59, 185 (1990) 
130. Wilbrink B, Bijlsma JWJ, Huber-Bruning O, Van Roy JLAM, Den Otter W, Van Eden W. Mycobacterial antigens stimulate rheumatoid mononuclear cells to cartilage proteoglycan depletion. J. Rheumatol. 17, 532 (1990). -5

1991
131. De Mik HJI, Koten JW, Maas RA, Dullens HFJ, Den Otter W. Tumour regression by IL-2 mediated stagnation of blood flow. In Vivo 5, 679 (1991). 
132. Denijn M, De Weger RA, Lips CJM, Van Unnik JAM, Den Otter W. Hy-bridohis-toche-mical demonstration of alternative splicing of the Calc-I gene. Am. J. Pathol. 138, 273 (1991). 
133. Den Otter W, Feron VF, Schaap LF (Editors): Groeifactoren, Hor-monen en Kan-ker; Basale en Klinisch Aspecten. Uitgave Utrecht Cancer Res. Centre (1991). 
134. Den Otter W, Maas RA, Koten JW, Dullens HFJ, Bernsen M, Klein WR, Rutten VPMG, Steerenberg PA, Balemans L, Ruitenberg EJ, Hill FWG, Heintz APM. Effective immu-notherapy with local low doses of interleu-kin-2. In Vivo 5, 561 (1991). -19
135. Dullens HFJ, Cluistra S, Van Os, Dux K, Den Besten PJ, Radema-kers LHPM, Den Otter W. Para-thy-mic lymphnodes during growth and rejection of intraperito-neally inoculated tu-mor cells. Invasi-on and Metastasis 11, 216 (1991). -10
136. Dullens HFJ, De Wit CL. Cancer therapy with interleukins 1, 4 and 6 and combi-nations of cytokines: A review. In Vivo 5, 567 (1991). 
137. Dullens HFJ, Wind JC, Maas RA, Bernsen MR, Vulto IM, Rademakers LHPM, Den Otter W. Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 ery-throleukemia cells. Int. Immunol. 3, 959 (1991). 
138. Ioannides CG, Den Otter W. Concepts in immunotherapy of Cancer. In Vivo 5, 551 (1991). 
139. Ioannides CG, Den Otter W (Editors). Immunotherapy and Cancer (1991). Special Issue of In Vivo. 
140. Koten JW, Den Otter W. The transition of benign to malignant in epithe-lial and mesen-chymal tumours. Anticancer Res. 11, 567 (1991). 
141. Koten JW, Den Otter W. Are omental milky spots an intestinal thymus? Lancet 338, 9 november 1991. 
142. Maas RA, Dullens HFJ, Den Otter W. Mechanisms of tumor regression induced by low doses interleukin-2. In Vivo 5, 637 (1991). 
143. Maas RA, Van Weering HJ, Dullens HFJ, Den Otter W. Intratumoral low-dose interleu-kin-2 induces rejection of distant solid tumour. Cancer Immunol. Immunother. 33, 389 (1991). 
144. Merchant TE, De Graaf PW, Nieuwenhuizen CWEA, Kievit HCE, Bak-ker CJG, Den Otter W. Fibroadenoma of the breast: in vivo magne-tic reso-nance characterization. Eur. J. Radiol. 13, 91 (1991). 
145. Merchant TE, Meneses P, Gierke LW, Den Otter W, Glonek T. 31P magnetic resonance phospholipid profiles of neoplastic human breast tissue. Br. J. Cancer 63, 693 (1991). 
146. Merchant ThE, Thelissen GRP, De Graaf PW, Den Otter W, Glonek T. Clinical Magnetic Resonance Spectroscopy of Human Breast Disease. Investigative Radiol. 26, 1053 (1991). 
147. Nietfeld JJ, Wilbrink B, Huber-Bruning O, Bijlsma JWJ, Den Otter W. Degradation of human cartilage by cytokines in vitro. Ann. Rheumatic Diseases 50, 967 (1991). 
148. Roholl PJM, Dullens HFJ, Kleijne J, Dubbink EJ, Den Otter W. Acid ethanol fixation and polyesterwax embedding combines preservation of antigenic deter-mi-nants with good morphology and enables simultaneous bromodeoxyuridine (BrdU) labeling. Bio-technic & Histochem. , p. 55 (1991). -
149. Roholl PJM, Weima SM, Prinsen I, De Weger RA, Den Otter W, Van Un-nik JAM. Expression of growth factors and their receptors on human sarcomas. Immunohistochemical detection of platelet-derived growth factor, epidermal growth factor and their re-ceptors. The Cancer Journal 4, 83 (1991). -7 83 (1991). �32732 to Editor) -5y with interleukin-2 and interleukin-12. 
150. Rutten VPMG, De Jong WAC, Klein WR, Den Otter W, Steerenberg PA, Ruiten-berg EJ. Immunotherapy of bovine ocular squamous cell carcinoma: isolation, culture and cha-racterization of lymphocytes present in the tumor. Anticancer Res. 11, 1259 (19-91). 
151. Rutten VPMG, Klein WR, De Jong WAC, Misdorp W, Steerenberg PA, De Jong WH, Den Otter W, Ruitenberg EJ. Immunotherapy of bovine ocular squamous cell carcinoma (BOSCC) by repeated intralesio-nal injec-tions of live BCG or BCG cell walls. Cancer Immunol. Immunother. 34, 186 (1991). 
152. Steerenberg PA, Geerse E, De Jong WH, Burger R, Scheper RJ, Den Otter W. Tumour rejection after adoptive transfer of line-10-immune spleen cells is medi-ated by two T-cell subpopulations. Cancer Immunol Immu-nother. 34, 103 (1991). 
153. Steerenberg PA, De Jong WH, Geerse E, De Graaf A, Scheper RJ, Den Otter W. Major histocompatibility complex class II antigen expression on leucocyte subpo-pulations in the draining lymph node and tumour in the early phase of bacillus-Calmette-Gu�rin-in-duced tumour regression. Cancer Immunol. Immunother. 33, 189 (1991). 
154. Wilbrink B, Nietfeld JJ, Den Otter W, Van Roy JLAM, Bijlsma JWJ, Huber-Bruing O. Role of TNF-? in relation to IL-1 and IL-6 in the proteoglycan turno-ver of hu-man articular cartilage. Br. J. Rheumatol. 30, 265 (1991) -39
1992

155. Bergers JJ, Den Otter W, De Groot JW, De Blois AW, Dullens HFJ, Stee-renberg PA, Crom-melin DJA. Reconstituted membranes of tu-mour cells (proteoliposomes) induce specific protection to mu-rine lymphoma cells. Cancer Immunol. Immunot-her. 34, 233 (199-2). 
156. Bernsen M, Dullens HFJ, Den Otter W, Heintz APM. Chemo-immuno-the-rapy of cancer with a combination of low dose Cisplatin and low dose recombinant inter-leukin-2. In: Ovarian Cancer 2; Biology, Diagnosis and Management (Eds: F Sharp, WP Masen, W Creasman, Chapman and Hall, London, 1992, pp. 189.

157. Denijn M, De Weger RA, Den Otter W, Van Unnik JAM, Lips CJM. Ex-pression of the first calcitonin/CGRP-gene in spontaneous and transplanted rat medullary thyroid carcinoma: A comparison of dot-blot analysis, in situ hybridization, and immunohistoche-mistry. J. Histo-chem. Cytochem 40, 1761 (1992). 
158. Maas RA, Dullens HFJ, Den Otter W. T cells and tumors. Immunol. Today 13, 78 (1992) (Letter) 
159. Maas RA, Roest PAM, Becker MJ, Weimar IS, Dullens HFJ, Den Otter W. Effec-tor cells of low-dose IL-2 immunotherapy in tumor bearing mice: Tumor cell killing by CD8+ cyto-toxic T-lymphocytes and macrophages. Immunobiol. 186, 214 (1992). 
160. Merchant ThE, Characiejus D, Kasimos JN, Den Otter W, Gierke LW, Glonek T. Phosphodiesters in saponified extracts of human breast and colon tumors. Magnetic Resonance in Medicine 25, 121 (1992). 
161. Rutten VPMG, Klein WR, De Jong WAC, Quint W, Den Otter W, Rui-tenberg EJ, Mel-chers WJG. Search for bovine papilloma virus DNA in bovine ocular squa-mous cell carcinoma (BOSCC) and BOSCC de-rived cell lines. Am J. Veterinary Res. 53, 1477 (1992). 
162. Wilbrink B, Holewijn M, Bijlsma JWJ, Van Roy JLAM, Van der Zee R, Boog CJP, Den Otter W, Van Eden W. Antigen-activated T-cells inhibit cartilage pro-teoglycan snthesis independently of T-cell proliferation. Scand. J. Immunol. 36, 733 (1992). 
163. Wilbrink B, Vernooy J, Den Otter W, Van Roy JLAM, Huber J, Huber-Bruning O. Influence of rheumatoid synovial fluid and cells on proteogly-cans in human cartilage explants. Modulation by piroxicam. Clin. Rheumatol. 11, 86 (1992). 
164. Gloudemans T, Pospiech I, Van der Ven LTM, Lips CJM, Schneid H, Den Otter W, Sus-senbach JS. Expression and CpG methylation of the insulin-like growth factor II gene in human smooth muscle tumors. Cancer Res. 52, 6516 (1992).

1993

165. Balemans LTM, Mattijssen V, Steerenberg PA, Van Driel BE, De Mulder PHM, Den Otter W. Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity. Cancer Immunol. Immunother. 37, 7 (1993). 
166. Bergers JJ, Den Otter W, Dullens HFJ, Kerkvliet CTM, Crommelin DJA. Inter-leukin-2 containing liposomes: Interaction of inter-leukin-2 with liposomal bilay-ers and preliminary studies on application in cancer vaccins. Pharmaceut. Re-s. 10, 1715 (1993). 
167. Bergers JJ, Den Otter, W, Dullens HFJ, De Groot JW, Steerenberg PA, Mimpen MWH, Crommelin DJA. Critical factors for liposome incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice. Cancer Immunol. Immu-nother. 37, 271 (1993). 
168. Bergers JJ, Storm G, Den Otter W. Liposomes as vehicles for the presentatin of tumor-associated antigens to the immu-ne system. In: Liposome Technology, Vol. II, 2nd ed. (ed. G. Gregoriadis), CRC Press, Boca Raton, Fl. , 1993, pp. 141-165. 
169. Bernsen MR, Van Barlingen HJJ, Van der Velden AW, Dullens HFJ, Den Otter W. Heintz APM. Dualistic effects of of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor dependent phenomenon. Int. J. Cancer 54, 513 (1993). 
170. Denijn M, De Weger RA, Van Unnik JAM, Den Otter W, Lips CJM. De-tection of calci-tonin and calcitonin gene-related peptide mRNA in human medullary thy-roid carcinoma. A retrospective study. J. Pathol. 169, 53 (1993). 
171. Den Otter W, Koten JW, Maas RA, Der Kinderen DJ. Are atopic disorders due to a TH2 clone? Br. J. Dermatol. 128, 102 (1993). 
172. Den Otter W, Hill FWG, Klein WR, Koten JW, Steeren-berg PA, De Mulder PHM, Rutten VPMG and Ruitenberg EJ. Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res. 13, 2453 (1993). 
173. Den Otter W, Merchant TE, Beijerinck D, Koten JW. Exclusion from mam-mographic screening of women genetically pre-disposed to breast cancer will probably elimi-nate mammographically induced breast cancer. Anticancer Res. 13, 1113 (1993). 
174. Dullens HFJ, Rademakers LHPM, Doffemont M, Van Veen PTh, Bulder R, Den Otter W. Involvement of the omental lymphoid organ in the induction of peritoneal immuni-ty aga-inst tumor cells. Invasion and Metastasis 13, 267 (1993). 
175. Gloudemans T, Pospiech I, Van der Ven LTM, Lips CJM, Den Otter W, Sussenbach JS. An AvaII restriction fra-gment length polymorphism in the insulin-like growth factor II gene and the occurrence of smooth muscle tumors. Cancer Res. 53, 5754 (1993). 
176. Koten JW, Neijt JP, Zonnenberg BA, Den Otter W. The difference between benign and malignant tumours explained with the 4-mutation paradigm for carcinogenesis. Anticancer Res. 13, 1179 (1993). 
177. Maas RA, Dullens HFJ, Den Otter W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol. Immunother. 36, 141 (1993). 
178. Maas RA, Becker MJ, Weimar IS, De Nooy JC, Dullens HFJ, Den Otter W. Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T-lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice. Immunobiol. 188, 281 (1993) 
179. Maas RA, Dullens HFJ, Van Weering DHJ, De Mik HJI, Koten JW, Belger RJ, Den Otter W. Histolo-gical analysis of IL-2 induced regression of murine solid SL2 tumors. Biothe-rapy 6, 83 (1993). 
180. Merchant TE, Den Otter W. et al. Breast disease evaluation with fat suppressed magnetic resonance imaging. Magnetic Reso-nance Imaging 11, 1119 (1993). 
181. Merchant TE, Thelissen GRP, De Graaf PW, Nieu-wenhui-zen CEWA, Kievit HCE, Den Otter W. Application of a mixed imaging sequence for MR imaging characterization of human breast disease. Acta Radiol. 34, 356 (1993). -9
182. Van der Ven LTM, Prinsen IM, Jansen GH, Roholl PJM, Defferrari R, Slater R, Den Otter W. Growth of cultured human glioma tumour cells can be regulated with his-tamine and histamine antagonists. Br. J. Cancer 68, 475 (1993). 
183. Van der Ven LTM, Rademakers LHPM, Angulo AF, Giltay JL, Wills I, Jansen G, Prinsen IM, Rombouts AGM, Roholl PJM, Den Otter W. Growth of mycoplasma transformed tTN129 cells depends on IGF-I. In Vitro Cell Dev. Biol. 29A, 517 (1993). 
184. Voshol H, Dullens HFJ, den Otter W, Vliegenthart JFG. Human natural killer cells: a convenient purification procedure and the influence of cryopre-servation on cytotoxic activity. J. Immunol. Meth. 165, 21-30 (1993). 
185. Voshol H, Dullens HFJ, Den Otter W, Vliegenthart JFG. Cell sur-face glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of gly-colipids and N-linked carbohydrate chains. Glycobiol. 3, 69 (1993). 
186. Wilbrink B, Holewijn M, Bijlsma JWJ, Van Roy JLAM, Den Otter W, Van Eden W. Suppression of human cartilage proteoglycan synthesis by rheumatoid synovial fluid mononuclear cells activated with mycobacterial 60-kd heat shock protein. Arthritis and Rheumatism 36, 514 (1993).

1994
187. Balemans LTM, Steerenberg PA, Koppenhagen FJ, Kremer BHA, De Mulder PHM, Claessen AME, Scheper RJ, Den Otter W. PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophosphamide. Int. J. Cancer 58, 871 (1994). 
188. Balemans LTM, Vegt PDJ, Steerenberg PA, De Boer EC, Van Swaaij A, De Vries REM, Van der Meij-den APM, Den Otter W. Effects of sequential intravesical admi-nistration of mitomycin C and bacillus Calmette-Guerin on the im-mune response in the guinea pig bladder. Urol. Res. 22, 239 (1994). 
189. Bergers JJ, Den Otter W, Crommelin DJA. Vesi-cles for tumour-associated antigen presentation to induce protec-tive immunity: preparation, characterization and en-han-ce-ment of the immune response by immunomodulators. J. Controlled Release 29, 317 (1994). 
190. Bergers JJ, Den Otter W, Dullens HFJ, De Groot JW, Steerenberg PA, Filius PMG, Crommelin DJA. Effect of immunomodulators on spe-cific tumor immu-nity indu-ced by li-posome-encapsulated tumor-associated anti-gens. Int. J. Cancer 56, 721 (1994). 
191. Hill FWG, Klein WR, Hoyer HJ, Rutten VPMG, Kock N, Koten JW, Steerenberg PA, Ruitenberg EJ, Den Otter W. Antitumor effect of locally injected low doses of re-com-binant human interleukin-2 in bovine vulval pa-pilloma and carcinoma. Vet. Immunol. Immunopathol. 41, 19 (1994). 
192. Hill FWG, Rutten VPMG, Hoyer HH, Klein WR, Koten JW, Steerenberg PA, Ruitenberg EJ, Den Ot-ter W. Local bacil-lus Calmette-Guerin therapy for bovine vulval papilloma and carcinoma. Cancer Immunol. Immu-nother. 39, 49 (1994). 
193. Nietfeld JJ, Duits AJ, Tilanus MGJ, Van de Bosch ME, Den Otter W, Capel PJA, Bijlsma JWJ. Antisense oligonucleotides, a novel tool for the control of cytokine effects on human cartilage. Arthritis and Rheumatism 37, 1357 (1994). 
194. Stassar MJJG, Vegt PDJ, Steerenberg PA, Van der Meijden APM, Meiring HD, Dessens-Kroon M, Geertzen HGM, Den Otter W. Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG the-rapy for superficial bladder cancer. Urol. Res. 22: 177 (1994). 
195. Vandebriel RJ, De Weger RA, Van Loveren H, Garssen J, Van Pop-pel MNM, Van Wichen DF, Den Ot-ter W. Specific T-cell factors that initiate cellular immune responses are produced by CD4-, CD8-, V�8- lymphocytes and are pre-sent in nude mice. Cell. Immunol. 159: 1 (1994). 
196. Van der Ven LTM, Gloudemans T, Roholl PJM, Van Buul-Offers SC, Bladergroen BA, Welters MJP, Sussenbach JS, Den Otter W. Growth advantage of hu-man leiomyo-ma cells compared to normal smooth muscle cells due to enhan-ced sensitivity toward insulin-like growth factor I. Int. J. Cancer 59, 427 (1994).

1995
197. Balemans LTM, Steerenberg PA, Kremer SHA, Koppenhagen FJ, De Mulder PHM, Den Otter W. Reduction of therapeutic efficacy by a second cycle of PEG-IL2. J. Immunother. 18, 45 (1995). 
198. Balemans LTM, Steerenberg PA, Kremer BHA, Koppenhagen FJ, De Mulder PHM, Den Otter W. Specific tumor memory induced by polyethylene-glycol-modified interleukin-2 requires both helper and cytotoxic T cells. Cancer Immunol. Immunother. 40, 125 (1995) 
199. Bernsen MR, Dullens HFJ, Den Otter W, Heintz APM. Re-evaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2. J. Interferon and Cytokine Res. 15, 641 (1995) 
200. Den Otter W, Hill FWG, Klein WR, Everse LA, Ruitenberg EJ, Van der Ven LTM, Koten JW, Steerenberg PA, Faber JAJ, Rutten VPMG. Ocular squamous cell carcinoma in Simmental cattle in Zimbabwe. Am. J. Vet. Res. 56, 1440 (1995) 
201. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rhode C, Stewart R, Faber JAJ, Ruitenberg EJ, Rutten VPMG. Therapy of bovine ocular squamous cell carcinoma with local doses of Interleukin-2 : 67% complete regressions after 20 months of follow-up. Cancer Immunol. Immunther. 41, 10 (1995).

1996
202. Bergers JJ, Den Otter W, Crommelin DJA. Liposome based cancer vaccines. J. Liposome Res. 6, 339 (1996). 
203. Den Otter W, De Groot JW, Bernsen MR, Heintz APM, Maas R, Hordijk GJ, Hill FWG, Klein WR, Ruitenberg EJ, Rutten VPMG. Optimal regimes for local IL-2 tumour therapy. Int. J. Cancer 88, 400 (1996). 
204. Den Otter W, Merchant TE, Beijerinck D, Koten JW. Breast cancer induction due to mammographic screening in hereditarily affected women. Anticancer Res. 16, 3173 (1996). 
205. Everse LA, Bernsen MR, Dullens HFJ, Den Otter W. The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of IL-2 administration. J. Expl. Therapeutics and Oncol. 1, 231 (1996). 
206. Moll AC, Imhof SM, Koten JW, Bezemer PD, Kuit DJ, Bouter LM, Den Otter W, Tan KEWP. Second primary tumors in patients with hereditary retinoblastoma: A register-based follow-up study 1945-1994. Int. J. Cancer 67, 515 (1996). 
207. Moll AC, Imhof SM, Kuit DJ, Bouter LM, Den Otter W, Bezemer D, Koten JW, Tan KEWP. High parental age is associated with sporadic hereditary retinoblastoma. Hum. Genet. 98, 109 (1996). 
208. Moll AC, Koten JW, Lindenmayer DAE, Everse LA, Tan KEWP, Hamburg A, Faber JAJ, Den Otter W. Three histopathological types of retinoblastoma and their relation to hereditary and age of enucleation. J. Med. Genet. 33, 923 (1996). 
209. Steerenberg PA, Balemans LTM, Kremer BHA, Koppenhagen FJ, De Mulder PHM, Den Otter W. Reduction of therapeutic efficacy by a second cycle of PEG-IL-2. J. Immunother. 18, 45, 1995. 
210. Van der Ven LTM, Van Buul-Offers SC, Gloudemans T, Bloemen RJ, Roholl PJM, Sussenbach JS, Den Otter W. Modulation of insulin-like growth factor (IGF) action by IGF-binding proteins in normal, benign and malignant smooth muscle tissues. J. Clin. Endocrinol. Metab. 81, 3629 (1996) 
211. Voshol H, Dullens HFJ, Den Otter W, Vliegenthart JFG. The glycosylation profile of interleukin-2 activated human lymphocytes correlates to their antitumor activity. Anticancer Res. 16, 155 (1996) 
212. Krul MRL, Tijhaar EJ, Kleijne JAFW, Van Loon AM, Nievers MG, Schipper H, Van der Kolk M, Steerenberg PA, Mooi FR, Den Otter W. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol. Immunother. 43, 44 (1996).

1997
213. Den Otter W, Steerenberg PA, Van der Laan JW. Requirements of animal studies aimed to test the therapeutic potency of anticancer drugs. Anticancer Res. 17, 4074 (1997). 
214. Everse LA, Bernsen MR, Dullens HFJ, Den Otter W. Priming of the antitumor response promotes efficiency of interleukin-2 therapy. Cancer Immunol. Immunother. 44, 221 (1997).
215. Everse LA, Renes IB, J�rgenliempk-Schultz IM, Rutgers DH, Bernsen MR, Dullens HFJ, Den Otter W, Battermann JJ. Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A preclinical study. Int. J. Cancer 72, 1003 (1997) 
216. J�rgenliemk-Schulz I-M, Renes IB, Rutgers DH, Everse LA, Bernsen MR, Den Otter W, Battermann JJ. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant Interleukin-2 (rIL-2). Radiation Oncology Investigations 5, 54 (1997). 
217. Moll AC, Imhof SM, Bleeker-Wagemakers, Den Otter W, Bouter LM, Koten JW, Tan KEWP. Prevalence of mental retardation in patients with hereditary retinoblastoma. Ophthalmic Genetics 18, 217 (1997). 
218. Moll AC, Kuik DJ, Bouter LM, Den Otter W, Bezemer PD, Koten JW, Imhof SM, Tan KEWP. Incidence and survival of retinoblastoma in The Netherlands; a register-based study 1862-1995. Br. J. Ophthalmol. 81, 559 (1997) 
219. Rutten VPMG, Klein WR, Den Otter W, Hill FWG, Ruitenberg EJ. Immunotherapy of bovine ocular squamous cell carcinoma and bovine vulval papilloma and carcinoma with IL-2. In: Cytokines in Veterinary Medicine (Schijns VECJ and Horzinek MC, eds), CAB International 1997. 
220. Van der Ven LTM, Roholl PJM, Gloudemans T, Van Buul-Offers SC, Welters MJP, Bladergroen BA, Faber JAJ, Sussenbach JS, Den Otter W. Expression of insulin-like growth factors (IGFs), their receptors and IGF-binding protein-3 in normal, benign and malignant smooth muscle tissues. Br. J. Cancer 75, 1631 (1997) 
221. Van der Ven LTM, Van Buul-Offers SC, Gloudemans T, Roholl PJM, Sussenbach JS, Den Otter W. Histamine-stimulated expression of insulin-like growth factors in human glioma cells. Br. J. Cancer 75, 1091 (1997) 
222. Van Loo PLP, Everse LA, Bernsen MR, Baumans V, Hellebrekers LJ, Kruitwagen CLJJ, Den Otter W. Analgesics in mice used in cancer research: reduction of discomfort? Lab. Animals 31, 318 (1997).

1998
223. Bernsen MR, Van Der Velden AW, Everse LA, Dullens HFJ, Den Otter W, Heintz APM. Interleukin-2: Hope in case of Cisplatin resistant tumors. Cancer Immunol. Immunother. 46, 41-47 (1998). 
224. Brinkert AW, Moll AC, Jager MJ, Den Otter W, Koten JW, Faber JAJ, Tan KEWP. Distribution of tumors in the retina in hereditary retinoblastoma patients. Ophthalmic Genetics 19, 63 (1998). 
225. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M. Intravesical IL-2 to treat T1 papillary bladder carcinoma: regression of marker lesions in 8 out of 10 patients. J. Urol. 159, 1183-1186 (1998) 
226. Den Otter W, Dobrowolski Z, Papla B, Van der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M. Discussion with Gomella et al. on Intravesical Interleukin-2 in T1 papillary bladder carcinoma. J. Urol. 160,1808 (1998)
227. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M. Behandeling van T1 papillair blaascarcinoom met intravesical IL-2: regressie van tumormarker bij 8 van de 10 behandelde patienten. Ned. Tijdsch. v. . Urologie 6, 43 (1998). 
228. Den Otter W, Merchant ThE, Beijerinck D, Koten JW. Inductie van borstkanker door mammografie. Kanker 22/4, 18 (1998). 
229. Den Otter W, Merchant ThE, Beijerinck D, Koten JW. Inductie van borstkanker door mammografie- II. Kanker 22, 20-21 (1998). 
230. Fiszer-Maliszewska L, Den Otter W, Madej JA, Mordarski M. Therapeutic potential of biological response modifiers against transplantable mouse tumors of spontaneous origin. II. Local Interleukin 2 treatment of tumors of different immunogenic strength. Archivum Immunologiae et Therapiae Experimentalis 46, 293-300 (1998).

1999
231. Bernsen MR, Tang J-W, Everse LA, Koten JW, Den Otter W. Interleukin-2 (IL-2) therapy : potential advances of locoregional versus systemic administration. Cancer Treatment Rev. 25,73-82 (1999)
232. Bubenik J, Huland E, Den Otter W (Editors). Abstracts of the First Symposium on local cytokine therapy of cancer : Interleukin-2, Interferon and related cytokines. Anticancer Res. 19, 1995-2006 (1999). 
233. Cad�e JA, De Kerf M, De Groot CJ, Den Otter W, Hennink WE. Synthesis, characterization of 2(methacryloyloxy)ethyl-(di)L-lactate and their application in dextran-based hydrogels. Polymer 40,6877-6882 (1999). 
234. Den Otter W. Interleukin-2 therapy of cancer in veterinary medicine. Vet. Immunol. Immunopathol 72, 379-380 (1999). 
235. Den Otter W. Evaluation: Complementarity and contradictoriness of cancer theories. A genetic perspective. Anticancer Res. 19, 4913-4914 (1999) -1
236. Den Otter W, Koten JW. A 4-mutation model of carcinogenesis for tumour suppressor genes. Anticancer Res. 19, 4845-4852 (1999) 
237 Den Otter W, Root-Bernstein R, Koten JW. What is cancer? Theories on carcinogenesis". Anticancer Res. 19, 4599, (1999). 
238. Den Otter W, Cad�e J, Gavhumende R, De Groot CJ, Hennink WE, Stewart R. Effective cancer therapy with a single injection of interleukin-2 at the site of the tumour. Cancer Immunol Immunother. 48, 419-420 (1999) 
239. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M. Answering letter Re �Intravesical Interleukin-2 in T1 papillary bladder carcinoma: Regression of marker lesion in 8 out of 10 patients �. J Urol 162, 1706 (1999)
240. Den Otter W and 19 other authors. Local low-dose IL-2 therapy. Hepato-Gastroenterol 46,1280-1286 (1999) -12
241. Fiszer-Maliszewska L, Den Otter W, Mordarski M. Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength. Cancer Immunol Immunother 47, 307-314 (1999)
242. Haneveld GT, Koten JW, Den Otter W. PATHOLOGIE. Geschiedenis. www. medweb. nl/dutch. soc. pathology; onder button : Vereniging
243. Koppenhagen FJ, Balemans LTM, Steerenberg PA, Jagmont TM, Den Otter W, Storm G. The design of a pharmaceutically acceptable liposomal formulation of recombinant interleukin-2 (rIL-2) for locoregional anticancer immunotherapy. J Liposome Res 9, 313-329 (1999)
244. Koten JW, Den Otter W. Suggestion for IL-2 treatment of conjunctival squamous cell carcinoma. Br. J. Ophthalmol 83, 995 (1999) (letter)
245. Koten JW, Beukers H, Den Otter W. History of cancer research in nosological perspective. Anticancer Res 19, 4613-4626 (1999)
246 Root-Bernstein R S, Den Otter W. Toward a philosophy of cancer research. Anticancer Res. 19, 4603-4612 (1999)

2000
247. Bubenik J, Den Otter W, Huland E. Local cytokine therapy of cancer : interleukin-2, interferons and related cytokines. Cancer Immunol Immunother 49, 116-122 (2000)
248. Cad�e JA, Van Luyn MJA, Brouwer LA, Plantinga JA, Van Wachem PB, De Groot CJ, Den Otter W, Hennink WE. In vivo biocompatibility of dextran-based hydrogels. J Biom Mater Res 50, 397-404 (2000)
249. Van Es RJJ, Baselmans AHC, Den Otter W, Van Dijk JE, Koole R, Den Otter W. Perilesional IL-2 treatment of a VX-2 head-and-neck cancer model can induce a systemic antitumor activity. Anticancer Research 20, 4163-4170 (2000)
250. Van Herpen CML, Mattijssen V, Balemans LTM, Den Otter W, De Mulder PHM. Locoregional immunotherapy in head and neck squamous cell carcinoma. In : New Frontiers in Immunobiology, p 251-258, Kugler Publications, Den Haag (2000)

2001
251. Cad�e JA, Van Steenbergen MJ, Versluis C, Heck AJR, Underberg WJM, DenOtter W, Jiskoot W, Hennink WE. Oxidation of recombinant human Interleukin-2 by potassium peroxodisulfate. Pharmaceutical Res 18, 1461 (2001)
252. Cad�e JA, Brouwer LA, Den Otter W, Hennink WE, Van Luyn MJA. A comparative biocompatibility study of microspheres based on crosslinked dextran or poly(lactic-co-glycolic) acid after subcutaneous injection in rats. J Biomed Mater Res 56 , 600-609 (2001)
253. De Groot CJ, Van Luyn MJA, Van Dijk-Wolthuis WNE, Cad�e JA, Plantinga JA, Den Otter W, Hennink WE. In vitro biocompatibility of biodegradable dextran-based hydrogels tested with human fibroblasts. Biomaterials 22, 1197-1203 (2001)
254. Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW, Den Otter W. A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 50, 226-227 (2001)
255. Den Otter W, Ziekman PGPM, Koten JW, Lygidakis NJ. Suggestions/requirements for a protocol to treat colorectal cancer with IL-2. Hepato-Gastroenterology 37, vol 48, jan-febr 2001 (no page number).

2002
256. Baselmans AHC, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W. The mechanism of regression of solid SL-2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 51, 492-498 (2002)
257. Cad�e JA, De Groot CJ, Jiskoot W, Den Otter W, Hennink WE. Release of recombinant human interleukin-2 from dextran-based hydrogels. J Controlled Release 78, 1-13 (2002)
258. Characiejus D, Pasukonine V, Kazlauskaite N, Valuckas KP, Petraitis T, Mauricas M, Den Otter W. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Research 22, 3679-3684 (2002)
259. De Groot CJ, Cad�e JA, Koten JW, Hennink WE, Den Otter W. Therapeutic efficacy of IL-2 loaded hydrogels in a mouse tumor model. Int J Cancer 98, 134-140 (2002)
260. Moiseeva EV, Bojenko VK, Fomina GG, Krasnovskaya OR, Krasilshchikova MS, Den Otter W. Can we predict individual mammary tumor growth rate in recipient mice? Baltic J Lab Anim Sci 12,74-83 (2002)
261. Moll AC, Imhof SM, Bouter L, Den Otter W, Koten JW. An infant with Down syndrome and retinoblastoma. A possible non-fortuitous association. Ophthalmic Genetics 23, 135-136 (2002)
262. Den Otter W, Steerenberg PA, Van der Laan JW. Testing therapeutic potency of anticancer drugs in animal studies : A commentary. Regulatory Toxicol Pharmacol 35, 266-272 (2002) -2

2003
263. Koten JW, Van Luyn MJA, Cad�e JA, Brouwer L, Hennink WE, Bijleveld C, Den Otter W. IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine24, 57-66 (2003)
264. Krastev Z, Koltchakov V, Alexiev A, Koten JW, Den Otter W. A case of hepatocellular carcinoma (HCC) treatment with local application of alcohol and interleukin-2 (IL-2). Hepato-Gastroenterol 50, 1647-1649 (2003)
265. Masztalerz A, Van Rooijen N, Den Otter W, Everse LA. Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol Immunother 52, 235-242 (2003)
266. Moiseeva EV, Merkulova IB, Bijleveld C, Koten JW, Miroshnikov AL, Den Otter W. Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer. Cancer Immunol Immunother 52, 487-496 (2003)
267. Spoormakers TJP, Klein WR, Jacobs JJL, Van den Ingh ThSGAM, Koten JW, Den Otter W. Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer Immunol Immunother 52,179-184 (2003)

2004
268. Bos GW, Jacobs JJL, Koten JW, Van Tomme S, Veldhuis T, Van Nostrum CF, Den Otter W, Hennink WE. In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy. Europ J Pharmaceutical Sciences 21, 561-567 (2004)
269. Kusznierczyk H, Pajtasz-Piasecka E, Koten JW, Bijleveld C, Krawczyk K, Den Otter W. Further development of local IL-2 therapy of cancer: Multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother 53, 445-452 (2004)
270. Masztalerz A, Everse LA, Den Otter W. Presence of cytotoxic B220+CD3+CD4-CD8- cells correlates with the therapeutic efficacy of lymphoma treatment with IL-2 and/or IL-12. J Immunother 27, 107-115 (2004)
271. Masztalerz A, Van Luyn M, Werner N, Molema G, Everse LA, Den Otter W. Treatment with IL-2 and IL-12 inhibits tumour cell division in SL2 lymphoma. Anticancer Research 24, 2633-2642 (2004)

2005
272. Bos GW, Hennink WE, Brouwer L, Den Otter W, Veldhuis TFJ, Van Nostrum R, Van Luyn MJA. Biocompatibility of in situ formed dextran hydrogels crosslinked by stereocomplex formation after subcutaneous implantation in rats. Biomaterials 26/8, 3901-3909 (2005)
273. Jacobs JJL, Sparendam D, Den Otter W. Local Interleukin-2 therapy is therapeutically most effective against cancer when injected intratumourally. Cancer Immunology Immunotherapy 54, 647-654.
274. Jacobs JJL, Hordijk GJ, J�rgenliemp-Schulz, Terhaard CHJ, Koten JW, Battermann JJ, Den Otter W. Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Accepted by Cancer Immunology Immunotherapy
275. Masztalerz A, Stewart R, Koten JW, Den Otter W. Anti-tumour effect of local IL-2 and IL-12 treatment in Bovine Vulval Papilloma Carcinoma Complex (BVPCC). Accepted by Veterinary Immunology and Immunopathology
276. Moiseeva EV, Rapoport EM, Bovin NV, Miroshnikov AI, Chaadaeva AV, Bojenko VK, Krasilschikova MS, Bijleveld C, Van Dijk JE , Den Otter W, Bovin NV. Galectins as markers of aggressiveness of mouse mammary carcinoma : Towards a lectin target therapy of human breast cancer. Accepted by Breast Cancer Research and Treatment
277. Stewart RJE, Masztalerz A, Jacobs JJL, Den Otter W. Local Interleukin-2 and Interleukin-12 therapy of bovine ocular squamous cell carcinomas. Accepted by Veterinary Immunology and Immunopathology
278. Stewart RJE, Hill FWG, Masztalerz A, Jacobs JJL, Koten JW, Den Otter W. Peritumoural low dose Interleukin-2 therapy of Bovine Ocular Squamous Cell Carcinomas : An effective therapy. Accepted by Veterinary Record

Professor Den Otter was promotor of the following theses

Information for doctors
(alleen in het engels)

Information for patients
Informatie voor patienten

Information about our research group
Informatie over onze onderzoeksgroep

I want to support this research
Ik wil dit onderzoek steunen